Anavex Life Sciences has reported promising results from its 48-week Phase 2 extension study
evaluating ANAVEX®2-73 (blarcamesine) for Parkinson’s disease dementia. The
clinical-stage biopharmaceutical company, listed on Nasdaq as AVXL, is
developing innovative therapies targeting neurodegenerative and neurodevelopmental disorders.
ANAVEX®2-73 is an oral small-molecule activator of the sigma-1 receptor (SIGMAR1). Data suggests
this activation is crucial in restoring neural cell homeostasis and promoting
neuroplasticity. In the context of Parkinson’s disease—a chronic, debilitating central
nervous system disorder—the drug has shown to be generally safe and
well-tolerated over the 48 weeks.
The Phase 2 study assessed various efficacy endpoints, including the Movement Disorder
Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), the REM Sleep
Behavior Disorder Screening Questionnaire (RBDSQ), and the Clinical Global
Impression – Improvement (CGI-I). Preliminary analysis demonstrated that
patients on ANAVEX®2-73 exhibited improvements across all measured endpoints.
Christopher U Missling, PhD, President & CEO of Anavex, expressed optimism regarding the
study’s outcomes. “The consistent improvement in patients’ clinical
symptoms over the 48 weeks highlights ANAVEX®2-73’s potential to address a
significant unmet need in Parkinson’s disease treatment,” he stated.
Anavex is poised to advance to a pivotal trial for Parkinson’s disease,
driven by these encouraging results. The company’s broader therapeutic product
platform includes ANAVEX®2-73 for Alzheimer’s disease, Rett syndrome, and other CNS disorders.
Additionally, Anavex has received a research grant from The Michael J. Fox Foundation for an
imaging-focused clinical trial with ANAVEX®2-73 in Parkinson’s disease.
As the aging population grows, the demand for effective treatments for neurodegenerative
diseases like Parkinson’s is likely to increase. With ANAVEX®2-73 showing
potential to slow and possibly reverse the symptoms of such conditions, Anavex
Life Sciences is at the forefront of innovative therapeutic development. Refer
to this article for related information.
Like their page on https://www.facebook.com/AnavexLifeSci/